» Articles » PMID: 6608388

Electromechanical Effects of Bepridil on Rabbit Isolated Hearts

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1984 Jan 1
PMID 6608388
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Electromechanical effects of a new antianginal agent, bepridil, on Langendorff-perfused rabbit hearts were compared with those of verapamil and lidocaine. Bepridil at concentrations above 2 X 10(-7)M caused a dose-related decrease in heart rate (HR), a prolongation of the atrio-His bundle conduction time (A-H interval) and a prolongation of the functional refractory period (FRP) of the atrioventricular (A-V) node. Similar changes in HR, A-H interval and the FRP of the A-V node were observed with verapamil at concentrations above 2 X 10(-8)M. Lidocaine at above 4 X 10(-5)M prolonged slightly the A-H interval and the FRP of the A-V node but did not decrease the HR. Bepridil at concentrations above 10(-6)M prolonged both the His bundle-ventricular conduction time (H-V interval) and the effective refractory period (ERP) of ventricular muscles. Similar changes in the H-V interval and in the ERP of ventricular muscles were observed with lidocaine at above 10(-5)M. Verapamil ranging between 5 X 10(-8)M and 8 X 10(-7)M had no effect on the H-V interval and appreciably shortened the ERP of ventricular muscles. Bepridil at concentrations above 2 X 10(-6)M reduced the developed tension as did verapamil at above 10(-7)M. On a molar basis, the depressant effect of bepridil on HR and the A-V nodal conduction, which may reflect inhibitory action on the slow channels, was less than one tenth that of verapamil. Bepridil was more potent than lidocaine in prolonging the H-V interval and the ERP of ventricular muscles indicating a possible inhibition of the fast sodium channels. Both of these electrophysiological effects of bepridil may afford significant bases for the antiarrhythmic action of the drug.

Citing Articles

Cross clinical-experimental-computational qualification of drug trials on human cardiac purkinje cells for proarrhythmia risk prediction.

Trovato C, Mohr M, Schmidt F, Passini E, Rodriguez B Front Toxicol. 2022; 4:992650.

PMID: 36278026 PMC: 9581132. DOI: 10.3389/ftox.2022.992650.


Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes.

Wang J, Kiyosue T, Kiriyama K, Arita M Br J Pharmacol. 1999; 128(8):1733-8.

PMID: 10588929 PMC: 1571802. DOI: 10.1038/sj.bjp.0702959.


Interactions between a "calcium channel agonist", Bay K 8644, and calcium antagonists differentiate calcium antagonist subgroups in K+-depolarized smooth muscle.

Spedding M, Berg C Naunyn Schmiedebergs Arch Pharmacol. 1984; 328(1):69-75.

PMID: 6083458 DOI: 10.1007/BF00496109.


Effects of bepridil and lidocaine on the intraventricular conduction in acutely ischaemic and infarcted canine myocardium.

Hashimoto H, Satoh N, Nakashima M Naunyn Schmiedebergs Arch Pharmacol. 1990; 342(6):683-90.

PMID: 2096300 DOI: 10.1007/BF00175713.

References
1.
Singh B, HAUSWIRTH O . Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J. 1974; 87(3):367-82. DOI: 10.1016/0002-8703(74)90080-5. View

2.
Rosen M, Ilvento J, Gelband H, Merker C . Effects of verapamil on electrophysiologic properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther. 1974; 189(2):414-22. View

3.
Wit A, Cranefield P . Effect of verapamil on the sinoatrial and atrioventricular nodes of the rabbit and the mechanism by which it arrests reentrant atrioventricular nodal tachycardia. Circ Res. 1974; 35(3):413-25. DOI: 10.1161/01.res.35.3.413. View

4.
Rosen M, Hoffman B, Wit A . Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine. Am Heart J. 1975; 89(4):526-36. DOI: 10.1016/0002-8703(75)90162-3. View

5.
Rosen M, Wit A, Hoffman B . Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am Heart J. 1975; 89(5):665-73. DOI: 10.1016/0002-8703(75)90514-1. View